About two-thirds of dulaglutide's blood pressure reduction in type 2 diabetes patients occurs through mechanisms independent of weight loss, suggesting the GLP-1 receptor agonist has direct cardiovascular benefits.
64% weight-independentNearly two-thirds of dulaglutide's systolic blood pressure reduction occurs through mechanisms other than weight loss
What the researchers found
In a meta-analysis of five placebo-controlled trials, dulaglutide 1.5 mg reduced systolic blood pressure by −2.6 mmHg (95% CI: −3.8 to −1.5; p<0.001) compared to placebo. Mediation analysis revealed that 36% of this effect was weight-dependent (−0.9 mmHg) and 64% was weight-independent (−1.5 mmHg).
For pulse pressure, the total reduction was −2.5 mmHg, with 86% attributable to weight-independent mechanisms. Diastolic blood pressure showed minimal impact, with only a small weight-mediated effect. At the higher 4.5 mg dose, additional SBP and pulse pressure reductions beyond the 1.5 mg dose were primarily weight-mediated.
Why it matters
GLP-1 receptor agonists are primarily prescribed for blood sugar control and weight management, but their cardiovascular benefits are increasingly recognized. Understanding that most of dulaglutide's blood pressure effect is independent of weight loss suggests these drugs may have direct vascular or renal mechanisms — which could inform their use as part of comprehensive cardiovascular risk management in diabetes.
How the study worked
Mediation analysis was conducted across five randomized, placebo-controlled trials from the AWARD clinical program evaluating dulaglutide 1.5 mg over approximately 6 months. The analysis estimated the proportion of blood pressure change mediated by weight loss versus weight-independent pathways. Results were combined via random-effects meta-analysis. A separate analysis in AWARD-11 compared dulaglutide 4.5 mg vs. 1.5 mg to assess dose-response relationships.
What this study cannot tell us
The analysis is post-hoc, not a prospectively designed blood pressure trial. The mediation approach cannot definitively establish causation for weight-independent mechanisms. The specific biological pathways underlying the weight-independent effects were not identified. The trials had relatively short durations (~6 months), and long-term blood pressure effects may differ.
How to read the evidence
This is a post-hoc mediation analysis pooling data from five randomized, placebo-controlled clinical trials (AWARD program). The clinical trial foundation is strong, but the mediation analysis itself is exploratory.
When this study was published
Published in 2023, this study reflects the current wave of research investigating the multi-system benefits of GLP-1 receptor agonists beyond glycemic control.
The bigger picture
GLP-1 receptor agonists have emerged as blockbuster drugs for diabetes and obesity. Studies like this reveal that their benefits extend well beyond glucose and weight control. Understanding the pleotropic (multi-system) effects of GLP-1 drugs on blood pressure, inflammation, and vascular function is reshaping how clinicians think about these medications — potentially positioning them as cardiovascular drugs that also happen to lower blood sugar and weight.
Questions still open
- What specific biological mechanisms drive the weight-independent blood pressure reduction seen with dulaglutide?
- Would dulaglutide provide clinically meaningful blood pressure benefits in non-diabetic hypertensive patients?
- Do other GLP-1 receptor agonists like semaglutide show similar proportions of weight-independent blood pressure effects?
Common questions
If dulaglutide lowers blood pressure independently of weight loss, what else might be causing the effect?
Should people with high blood pressure but without diabetes consider GLP-1 drugs?
Read the original research
Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.
Cardiovascular diabetology, 22(1), 49
Citation
Ferdinand, Keith C; Dunn, Julia; Nicolay, Claudia; Sam, Flora; Blue, Emily K; Wang, Hui. (2023). Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.. Cardiovascular diabetology, 22(1), 49. https://doi.org/10.1186/s12933-023-01775-x